CA SB418

Requires health care service plans, health insurers, and Medi-Cal to cover up to a 12-month supply of FDA-approved prescription hormone therapy and necessary self-administration supplies when dispensed at one time, with provisions sunsetting January 1, 2035.

Prohibits health plans and insurers from using utilization controls to limit hormone therapy prescriptions to less than a 12-month supply, though controlled substances are limited to the maximum supply allowed under state and federal law.

Establishes comprehensive nondiscrimination protections prohibiting health plans and insurers from discriminating based on race, color, national origin, age, disability, or sex, with sex discrimination explicitly including gender identity, sexual orientation, sex characteristics, and pregnancy.

Bars health plans and insurers from denying or limiting coverage for gender transition or gender-affirming care based on an individual's sex assigned at birth, gender identity, or recorded gender, and prohibits categorical exclusions for such care.

Requires pharmacists to dispense up to a 12-month supply of prescription hormone therapy at a patient's request pursuant to a valid prescription, with exceptions for patient preference, prescriber instructions, or controlled substances.